Atossa Therapeutics (ATOS) issued the following statement in response to the Patent Trial and Appeal Board’s, PTAB, final written decision in PGR2023-00043 regarding U.S. Patent No. 11,572,334. Atossa is disappointed with the PTAB’s decision finding all challenged claims in the ‘334 patent unpatentable and is evaluating its options. This decision has no impact on the formulations currently in clinical development by Atossa. While Atossa disagrees with the decision and believes there are appealable issues, the Company will not be pursuing an appeal from the PTAB decision, given the cost and time involved. Instead, the Company intends to continue to pursue patent protection around the Company’s current formulations in clinical development, including in a new Continuation Patent Application to be filed with the U.S. Patent Office.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics issues letter to shareholders
- Atossa Therapeutics ‘applauds’ Surgeon General’s advisory on alcohol
- Atossa Therapeutics to present poster on Z-endoxifen at SABCS
- Atossa Therapeutics announces full result from KARISMA-Endoxifen trial
- Atossa Therapeutics announces resuts from Phase 2 KARISMA-Endoxifen study